About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDNCT01395264

Saccadometry in Primary Headache Syndromes

Migraine is one of the commonest neurological disorders, affecting up to 12% of the general population, but remains relatively under-diagnosed and under-treated. Migraine has a wide socioeconomic impa...

Lead sponsor: Tim Young•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Tim Young

As above

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Male or female and aged between 18 and 60 years in good general health apart from suffering from headaches (test group).
•2. Migraine and cluster headache will be diagnosed according to ICHD-II diagnostic criteria (6).
•3. Migraineurs must suffer at least two migraine attacks per year and no more than 5 attacks per month.
•\-

Exclusion Criteria

•1. Any other neurological disorder such as stroke, multiple sclerosis, epilepsy, concussion within the past year, psychiatric disorders, visual disorders.
•2. Use of migraine prophylactic medication in the last month or acute migraine therapy in the 3 days prior to testing.
•3. Patients on any medication to treat depression in their case
•4. Headache during testing or within 3 days before and after testing.
•\-

Related studies

Natural History of the Human Biological Response to Environmental Exposure and Injury

NCT04888923 · Inflammation, Normal Controls, and more

MMA Embolization for Refractory Chronic Migraine

NCT06735833 · Migraine

NSS Grocery Store Brazil

NCT07249008 · Control Group, Mexico-based NSS FOPL, and more

RECRUITINGPhase 3

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505 · Chronic Migraine

RECRUITINGPhase 3

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

NCT06241313 · Migraine

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 31, 2017Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment42

Start dateAug 2011

Last updatedOct 31, 2017

Condition

Migraine Cluster Headache Control Menstrual Migraine

Locations shown

Neurology Department, Whittington Hospital

London

The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, and The John Radcliffe hospital, Oxford, The Whittington Hospital N19 5NF London

London

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 31, 2017Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions